復星醫藥(600196.SH):禪城醫院及復星醫療擬向豫園股份轉讓佛山禪曦100%股權及相關債權
格隆匯 4 月 26日丨復星醫藥(600196.SH)公佈,為聚焦主業,控股子公司禪城醫院及復星醫療擬向豫園股份轉讓所持有的佛山禪曦合計100%的股權以及截至2020年12月31日因股東借款而形成的對佛山禪曦的債權,此次轉讓總價為人民幣5.5億元,其中:股權轉讓價款人民幣17611.28萬元、債權轉讓價款人民幣37388.72萬元。
同時,佛山禪曦與禪城醫院將繼續履行2020年1月簽訂的《定製協議》,由佛山禪曦為禪城醫院定製建設用於運營婦女兒童醫學中心、養護院的相關物業(即“禪醫健康城綜合體項目”中的第5座住院樓和第6座養護院,以下合稱“定制工程”),於該等定製工程完成竣工驗收備案後及時交付禪城醫院使用,並以資產轉讓的方式將定製工程的產權辦理至禪城醫院名下。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.